Among patients with worsening renal function, rivaroxaban reduced stroke or systemic embolism compared with warfarin (1.54 vs 3.25 events per 100 patient-years; P=0.050 for interaction).
RCT (n=12,612)
randomly assigned
Does rivaroxaban reduce stroke or systemic embolism compared with warfarin in patients with atrial fibrillation and worsening renal function?
In patients with atrial fibrillation who develop worsening renal function, rivaroxaban is associated with lower rates of stroke and systemic embolism compared with warfarin, without an increased risk of bleeding.
Absolute Event Rate: 1.54% vs 3.25%
p-value: p=0.050 for interaction
BACKGROUND: Despite rapid clinical adoption of novel anticoagulants, it is unknown whether outcomes differ among patients with worsening renal function (WRF) taking these new drugs compared with warfarin. We aimed to determine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) differed among participants with WRF taking rivaroxaban and those taking warfarin. METHODS: After excluding patients without at least 1 follow-up creatinine measurement (n=1624), we included all remaining patients (n=12 612) randomly assigned to either rivaroxaban or dose-adjusted warfarin. On-treatment WRF (a decrease of >20% from screening creatinine clearance measurement at any time point during the study) was evaluated as a time-dependent covariate in Cox proportional hazards models. RESULTS: Baseline characteristics were generally similar between patients with stable renal function (n=9292) and WRF (n=3320). Rates of stroke or systemic embolism, myocardial infarction, and bleeding were also similar, but WRF patients experienced a higher incidence of vascular death versus stable renal function (2.21 versus 1.41 events per 100 patient-years; P=0.026). WRF patients who were randomized to receive rivaroxaban had a reduction in stroke or systemic embolism compared with those taking warfarin (1.54 versus 3.25 events per 100 patient-years) that was not seen in patients with stable renal function who were randomized to receive rivaroxaban (P=0.050 for interaction). There was no difference in major or nonmajor clinically relevant bleeding among WRF patients randomized to warfarin versus rivaroxaban. CONCLUSIONS: Among patients with on-treatment WRF, rivaroxaban was associated with lower rates of stroke and systemic embolism compared with warfarin, without an increase in the composite bleeding end point. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00403767.
Fordyce et al. (Wed,) conducted a rct in Atrial Fibrillation with worsening renal function (n=12,612). Rivaroxaban vs. Dose-adjusted warfarin was evaluated on Stroke or systemic embolism (p=0.050 for interaction). Among patients with worsening renal function, rivaroxaban reduced stroke or systemic embolism compared with warfarin (1.54 vs 3.25 events per 100 patient-years; P=0.050 for interaction).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: